# A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer

> **NCT04809805** · PHASE1 · TERMINATED · sponsor: **Bayer** · enrollment: 5 (actual)

## Conditions studied

- Metastatic Melanoma and Other Solid Tumors

## Interventions

- **DRUG:** BAY2666605

## Key facts

- **NCT ID:** NCT04809805
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-15
- **Primary completion:** 2022-11-09
- **Final completion:** 2023-04-27
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Due to the high probability of not achieving a therapeutic window and lack of evidence of sufficient clinical benefit.
- **Last updated:** 2023-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04809805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04809805, "A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04809805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*